Search results
Results From The WOW.Com Content Network
The trial enrolled pediatric and adult participants (including pregnant women) with Zaire ebolavirus infection. [3] All participants received standard, supportive care for the disease. [3] The participants and the health care providers knew which treatment was being given. [3] The primary efficacy endpoint was 28-day mortality. [2]
The Ervebo vaccine, developed by Merck, is a single-dose vaccine. It works by using a modified virus to produce antibodies against Ebola, equipping the immune system to recognise and neutralise ...
Researcher working with the Ebola virus while wearing a BSL-4 positive pressure suit. There is a cure for the Ebola virus disease that is currently approved for market the US government has inventory in the Strategic National Stockpile. [1] For past and current Ebola epidemics, treatment has been primarily supportive in nature. [2]
Post-Ebola virus syndrome (or post-Ebola syndrome) is a post-viral syndrome affecting those who have recovered from infection with Ebola. [3] Symptoms include joint and muscle pain, eye problems, including blindness, various neurological problems, and other ailments, sometimes so severe that the person is unable to work. [ 4 ]
Symptoms of Ebola usually show up between eight and 10 days after a person is infected, the CDC says, and they usually progress from “dry” symptoms like a fever, aches, and pains, to “wet ...
In fact, the nature of Ebola - which is spread by close contact with bodily fluids and blood - means that any modern hospital using standard, rigorous, infection-control measures should be able to ...
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication used for the treatment of Zaire ebolavirus (Ebolavirus) infection. [2] [3]The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection.
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. [1] Symptoms typically start anywhere between two days and three weeks after infection. [ 3 ]